Drug intelligence / Profile preview

Lactobacillus acidophilus L-92

Development stage
Phase 3
Lead developer
Asahi Group Holdings
Modality
Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration
Oral
01

Overview

Lactobacillus acidophilus L-92 is a specific strain of probiotic bacteria, often used in a heat-killed (paraprobiotic or postbiotic) form. [5, 6, 11, 12] It was developed by the Japanese company Asahi Group, stemming from its research on Calpis cultured milk products. [1, 3] L-92 has been clinically studied for its ability to alleviate symptoms of allergic conditions, most notably atopic dermatitis in both adults and children. [3] Studies show that oral administration can significantly reduce the severity of skin symptoms. [3] It is also investigated for hay fever and perennial allergic rhinitis. [3] The proposed mechanism of action is immunomodulation; it is believed to suppress T-helper 2 (Th2)-dominant inflammation by promoting a balanced Th1/Th2 immune response and activating regulatory T cells. [5, 12] This leads to changes in inflammatory markers, such as increased production of TGF-β and IL-12 and reduced levels of IgE and eosinophils. L-92 is available as a functional food ingredient and is sold in various consumer products, including drinks, powders, and capsules. [2, 8, 9]

Brand names
CALPIS Protective L-92 Lactic Acid DrinkDear Natura Gold L-92CALPIS Aller careAller-Aid L-92Style Balance Immune Support
Other names
heat-killed Lactobacillus acidophilus L-92paraprobiotic Lactobacillus acidophilus L-92L92L-92L 92
02

Targets

PRR (Pattern recognition receptors)

Beyond the preview

Go deeper on Lactobacillus acidophilus L-92.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lactobacillus acidophilus L-92.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call